|| List of recent Peptide-related patents
|Multi-gene expression vehicle|
A multigene expression vehicle (mgev) consisting essentially of a polynucleotide comprising 2 to 8 domain segments, d, each domain encoding a functional protein, each domain being joined to the next in a linear sequence by a linker (l) segment encoding a linker peptide, the d and l segments all being in the same reading frame, and at least one of the domains is not a type two protease inhibitor.. .
|Constitutively active aba receptor mutants|
The present invention provides for compositions comprising mutated pyr/pyl receptor polypeptides that bind to a type 2 protein phosphatase in the absence of abscisic acid. The present invention further provides for methods of making and using the mutated pyr/pyl receptor polypeptides..
|Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement|
Recombinant polynucleotides and recombinant polypeptides useful for improvement of plants are provided. The disclosed recombinant polynucleotides and recombinant polypeptides find use in production of transgenic plants to produce plants having improved properties..
|Polynucleotides and polypeptides involved in post-transcriptional gene silencing|
This invention relates to isolated nucleic acid fragments encoding polypeptides involved in post-transcriptional gene silencing. The invention also relates to construction of a recombinant dna construct encoding all or a portion of the polypeptide involved in post-transcriptional gene silencing, in sense or antisense orientation, wherein expression of the recombinant dna construct results in production of altered levels in a transformed host cell of the polypeptide involved in post-transcriptional gene silencing..
|Plant homolog to autophagy protein p62|
The present invention comprises recombinant dna molecule, expression cassette, dna vector, binary plasmid, plant cell and a method of polypeptide production in eukaryotic organism and use thereof. In more details, it provides the means, through using methods of genetic engineering, of obtaining plants with advantageous breeding features, particularly with increased tolerance to abiotic stresses including mineral deficiency or plants useful for monitoring the process of autophagy..
|Process for the production of fine chemicals|
The present invention relates to a process for the production of a fine chemical in a non-human organism, like a microorganism, a plant cell, a plant, a plant tissue or in one or more parts thereof. The invention furthermore relates to nucleic acid molecules, polypeptides, nucleic acid constructs, expression cassettes, vectors, antibodies, host cells, plant tissue, propagation material, harvested material, plants, microorganisms as well as agricultural compositions and to their use..
|Ionic tags for synthesis of oligoribonucleotides|
The invention relates to the chemical synthesis of oligonucleotides, e.g., oligoribonucleotides. In another aspect, the invention relates to compounds of formula (ii) processes for making these compounds, and the use thereof in the chemical synthesis of oligonucleotides, e.g., oligoribonucleotides.
|Stabilized variant maml peptides and uses thereof|
Internally cross-linked peptides derived from human maml and derivatives thereof which exhibit affinity for the icn1-csl complex are described and characterized. The peptides can interfere with notch signaling and are thus useful for treating various disorders, including certain cancers..
|Method for synthesizing proteins|
Method for assembling proteins from peptide fragments. It allows the production of proteins in a manner that is simple, reliable and applicable on an industrial scale.
|Dual-aav vector-based systems and methods for delivering oversized genes to mammalian cells|
Disclosed are materials and methods for treating diseases of the mammalian eye, and in particular, usher syndrome 1b (ush1b). The invention provides aav-based, dual-vector systems that facilitate the expression of full-length proteins whose coding sequences exceed that of the polynucleotide packaging capacity of an individual aav vector.
Isolated polynucleotides comprising a fev mini-promoters are provided. The mini-promoter may be operably linked to an expressible sequence, e.g.
|Compositions and methods for short interfering nucleic acid inhibition of nav 1.8|
The invention provides short interfering nucleic acids, either single-stranded or double-stranded, that cause rnai-induced degradation of mrna from the na.sub.v1.8 sodium channel gene; to pharmaceutical compositions comprising such short interfering nucleic acids; recombinant vectors comprising such short interfering nucleic acids; a method for inhibiting translation of an mrna; a method for inhibiting expression of a polypeptide; a method for blocking the membrane potential in a cell; a method for blocking the sodium current in a cell; and a method for inhibiting chronic pain.. .
|Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients|
This invention relates to a method for managing the risk of an adverse interaction between teriflunomide and a substrate of breast cancer resistance protein (bcrp) and/or organic anion transporting polypeptide b1 and b3 (oatp1b1/b3).. .
|Use of agonists of formyl peptide receptor 2 for treating dermatological diseases|
The present invention relates to a method for treating dermal inflammation and dermal diseases by local or systemic delivery, in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of formyl peptide receptor 2 (fpr2).. .
|Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases|
The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of formyl peptide receptor 2.. .
|Polypeptides involved in immune response|
Novel polypeptides which comprise a receptor-ligand pair involved in t-cell activation are disclosed. Nucleic acid molecules encoding said polypeptides, and vectors and host cells for expressing same are also disclosed.
|Hjurp peptides and vaccines including the same|
Isolated peptides derived from seq id no: 50 and fragments thereof that bind to an hla antigen and induce cytotoxic t lymphocytes (ctl) and thus are suitable for use in cancer immunotherapy are described herein. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, provided they retain the requisite cytotoxic t cell inducibility of the original sequence.
|Kits and methods for the treatment of cancer using gliadin peptides|
Kits and methods for treating cancer comprising administration of a gliadin peptide to a patient are disclosed herein. A kit according to the invention comprises a pharmaceutical composition comprising a gliadin peptide and instructions for administering the peptide to a patient.
|Multi-leu peptides and analogues thereof as selective pace4 inhibitors and effective antiproliferative agents|
Disclosed herein are pace4 inhibitors, compositions comprising pace4 inhibitors and their uses thereof for lowering pace4 activity, reducing cell proliferation, reducing tumor growth, reducing metastasis formation, preventing and/or treating cancer. Also provided are methods for lowering pace4 activity, reducing the proliferation of a cell, reducing tumor growth and/or treating and preventing cancer.
|Extract and peptides derived from oryza sativa japonica group and uses thereof|
The invention relates to isolated peptides derived from oryza sativa japonica group, pharmaceutical compositions comprising same, and uses thereof for treating, preventing, ameliorating, and/or delaying the onset of inflammatory and/or neuroinflammatory and/or autoimmune diseases or conditions and in particular multiple sclerosis. The invention further relates to extracts from oryza sativa japonica group and use thereof as a dietary supplement or in a pharmaceutical composition for treating, preventing, ameliorating, and/or delaying the onset of inflammatory, and/or inflammatory, neuroinflammatory and/or autoimmune diseases or conditions.
|Peptides and compositions for treatment of joint damage|
The present invention provides new protease resistant polypeptides, as well as compositions and methods for treating, ameliorating or preventing conditions related to joint damage, including acute joint injury and arthritis.. .
|Compositions comprising fibrous polypeptides and polysaccharides|
Isolated polypeptides are disclosed comprising an amino acid sequence encoding a monomer of a fibrous polypeptide attached to a heterologous polysaccharide binding domain. Composites comprising same, methods of generating same and uses thereof are all disclosed..
|Anti-angiogenic molecules, nanostructures and uses thereof|
The disclosure is generally directed toward the design and synthesis of peptide amphiphile (pa) molecules that comprises a peptide configured to inhibit angiogenesis. The peptide amphiphile comprises a hydrophobic tail, peptide sequence capable of beta-sheet formation; and a peptide, wherein the peptide is configured to inhibit angiogenesis.
|Treatments for gastrointestinal disorders|
Described herein are peptides, compositions, and related methods for treating upper gastrointestinal disorders and conditions (e.g., dyspepsia, gastroparesis, post-operative gastric ileus, a functional esophageal disorder, a functional gastroduodenal disorder, gastroesophageal reflux disease (gerd), or a duodenal or stomach ulcer) as well as other conditions and disorders that are described herein.. .
|Use of epo-derived peptide fragments for the treatment of neurodegenerative disorders|
The described invention provides methods and kits for administering an epo-derived peptide to a subject suffering from a neurodegenerative disease. The epo-derived peptide delays the onset and/or progression of a neurodegenerative disease, limits cognitive impairment in, and prolongs the survival of, subjects suffering from a neurodegenerative disease..
|Compositions and methods for treating glioma|
Isolated peptides, compositions and methods of use for treating tumors infiltrated with macrophages, such as glioblastomas.. .
|Anti-amyloidogenic, alpha-helix breaking ultra-small peptide therapeutics|
The invention provides ultra-small peptide inhibitors that are capable of preventing amyloid formation/amyloidosis.. .
|Engineered poypeptides having enhanced duration of action and reduced immunogenicity|
Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides.
|Methods for reducing cd36 expression|
The invention provides a method for treating one or more complications of diabetes in a mammal. The method comprises administering to a mammal in need thereof an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3 pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1..
|Peptide-based quorum sensing inhibitors for the attenuation of virulence in staphylococcus aureus|
Compounds that affect quorum sensing (qs) in staphylococcus aureus and related staphylococcus species (e.g., s. Epidermidis).
|Peptide compositions that downregulate tlr-4 signaling pathway and methods of producing and using same|
Peptide compositions are disclosed that include fragments of surfactant protein-a, or a derivative thereof, wherein the fragment binds to tlr4. Methods of producing and using the peptide compositions are also disclosed..
|Modulation of structured polypeptide specificity|
The invention describes peptide ligands specific for human plasma kallikrein.. .
|Methods for accelerated selection of polypeptides|
In certain embodiments, the disclosure provides a method for generating an mrna-protein fusion molecule. In other embodiments, the disclosure provides a method for selecting a desired polypeptide..
|Indirect antigen-specific t cell recognition assay|
The present invention provides a method for analyzing simultaneously multiple human antigen-specific cell populations of a sample, the sample comprising b cells and antigen-specific cells, the method comprising a) separation of b cells from said sample, b) dividing the b cells into n sub-samples, c) differentially labeling the b cells of said sub-samples, wherein at least n-1sub-samples are labeled, d) pulsing of the b cells of each sub-sample with single or multiple peptides, e) pooling of the labeled and peptide-pulsed b cells with cells of said sample comprising said antigen-specific cells, f) co-cultivation of the cells of step e), g) flow cytometry analysis of the b cells with regard to their cell number and cd83 expression, thereby determining the potency of said antigen-specific cells in said sample.. .
|Detection of human endogenous retrovirus expression in cancer and normal cells|
The invention relates to human endogenous retrovirus env (herv-wl) polypeptides, nucleotide sequences, herv-wl antibodies, methods to detect cancer, and methods to determine the effectiveness of the treatment of cancer.. .
|Viral nanoarrys and sensors comprising the same|
The present invention provides arrays comprising polypeptides associated with viruses that are immobilized to an electrode in a directional orientation such that the surface area of the electrode and the sensitivity of the electrode is increased. The invention also provides for methods of diagnosing and/or prognosing a certain disease or disorder through contacting a sample from a patient with an array comprising the polypeptides associated with viruses..
|Method of generating an optimized, diverse population of variants|
The disclosure relates to a method of generating a diverse set of variants to screen improved and novel properties within the variant population, a system for creating the diverse set of variants, and the variant peptides.. .
|Cow rumen xylose isomerases active in yeast cells|
Polypeptides were identified among translated coding sequences from a metagenomic cow rumen database, that were shown to provide xylose isomerase activity in yeast cells. The xylose isomerase activity can complete a xylose utilization pathway so that yeast can use xylose in fermentation, such as xylose in biomass hydrolysate..
|Bacterial xylose isomerases active in yeast cells|
Specific polypeptides were identified as bacterial xylose isomerases that are able to provide xylose isomerase activity in yeast cells. The xylose isomerase activity can complete a xylose utilization pathway so that yeast can use xylose in fermentation, such as xylose in biomass hydrolysate..
|Compositions and methods of inhibiting neuronal cell death|
A method of inhibiting β-amyloid (aβ) induced neuronal cell death includes administering to a neuronal cell exposed to a neurotoxic amount of aβ a therapeutically effective amount of cell penetrating peptide (cpp). The cpp has an amino acid sequence that has at least 80% sequence identity to about 5 to about 41 consecutive amino acids of seq id no: 1..
|Peptide-bound gold metal nano-clusters as cancer cell killing agents|
Peptide-bound gold metal nanocluser complexes are produced to induce cancer cell death by dramatically inhibiting trxr activities of the cancer cells. Specificity is shown by selectively designing peptide sequences..
A bio-pin is provided. The bio-pin can be used for cell transfer and treatment, cell tracing, and targeting of specific tissues and cells using a peptide-based complex in which a cell-penetrating peptide or a cell-adhesive peptide is bound to one or both ends of a cell membrane protein, and used in a molecular imaging system, a medical appliance, and the like..
|In situ expression of lipase for enzymatic production of alcohol esters during fermentation|
Disclosed herein are methods of producing alcohol esters during a fermentation by providing alcohol-producing microorganisms which further comprise an engineered polynucleotide encoding a polypeptide having lipase activity.. .
The invention relates to recombinantly produced β-glucosidase variants with enhanced thermoactivity compared to naturally occurring proteins. The invention also provides methods for producing a variant β-glucosidase polypeptide with improved thermoactivity by identifying performance sensitive positions in a target β-glucosidase polypeptide and substituting the residue at that position with a thermoactivity enhancing residue..
|Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same|
The present invention provides isolated polypeptides having cellulolytic enhancing activity and polynucleotides encoding the polypeptides, catalytic domains, cellulose binding domains and polynucleotides encoding the polypeptides, catalytic domains or cellulose binding domains. The invention also provides nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains or cellulose binding domains..